Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04691297 · ClinicalTrials.gov registry record · NA
Digitally Enhanced Smoking Cessation for High Risk Smokers
A NA study of Smoking Cessation and Smoking, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 153
- Enrollment target
- 2
- Study locations
NCT04691297: Active NA study of Smoking Cessation and Smoking, sponsored by Dana-Farber Cancer Institute.
NCT04691297 is a NA study of Smoking Cessation and Smoking that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 153 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04691297, a NA study of Smoking Cessation and Smoking, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 153 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a research study, is testing a program to improve lung health through smoking cessation and providing education around lung screening. In this research study involves Studying the Enhanced Smoking Cessation Approaches to Promote Empowerment (ESCAPE) program compared to usual care. The ESCAPE program was developed help women with HIV quit smoking. Women in the ESCAPE program quit smoking and stayed quit for longer (up to 3 months). For this study, investigators have added a lung screening to the ESCAPE program and want to test if this will improve lung health through increasing quit rates and lung screening. .
Primary Outcome
biochemical verification of smoking status will be done and the %7-day point prevalence abstinence will be compared between two groups with exact binomial test,
Conditions Studied
Interventions
- OTHER Standard Care
- OTHER Escape
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2026-12-01 |
| Phase | NA |
What the registry record for NCT04691297 still lists
NCT04691297 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (68% lower).
The record links to 5 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Standard Care is the first listed.
NCT04691297 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04691297 about?
NCT04691297 is a clinical study titled "Digitally Enhanced Smoking Cessation for High Risk Smokers". This is a research study, is testing a program to improve lung health through smoking cessation and providing education around lung screening. In this research study involves Studying the Enhanced Smoking Cessation Approaches to Promote Empowerment (ESCAPE) program compared to usual care. The ESCA...
What is the current status of trial NCT04691297?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 153 participants. The study started on 2021-02-01. Estimated completion is 2026-12-01.
What conditions does trial NCT04691297 study?
This clinical trial studies the following conditions: Smoking Cessation, Smoking, Smoking Behaviors, Smoking, Tobacco, Lung Cancer Screening.
What interventions are being tested in trial NCT04691297?
The interventions under investigation include: Standard Care (OTHER), Escape (OTHER).
Who is sponsoring clinical trial NCT04691297?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04691297 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04691297's enrollment target sits among peer trials
153 102nd of 188 higher than 87 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy
RECRUITING · NA
-
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
RECRUITING · NA
-
ACT Lung Health Intervention: Phase Two
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
RECRUITING · NA
-
Urban and Reservation Implementation of All Nations Breath of Life
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI